CTIS2022-500449-26-00进行中（未招募）1 期
Pan-European proof-of-concept study comparing Decentralised Clinical Trial (DCT) and hybrid approaches to conventional clinical trial approaches in patients with Type 2 diabetes mellitus treated with Toujeo® - RADIA
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1) Participant with T2DM diagnosed for at least 1 year before the screening visit (V1)., 2) Participant treated as part of their treatment with a basal insulin (i.e. type of insulin and time/frequency of the injection), for at least 3 months before the screening visit., 3) The total daily basal insulin dose should be stable (±20%) for at least 1 month before the screening visit., 4) Signed written informed consent or e-consent depending on the arm., 5) Participant's mental and physical status allows them to be able to perform their activities of daily living with no or minimal assistance, including the ability to administer injectable insulin and measure their blood glycaemic level., 6) Willing and able to permit home visits (only for Part A of the study)., 7) Willing and able to comply with study drug receipt, accountability, and return processes and procedures., 8) Access to tablet/smartphone with Bluetooth functionality., 9) Access to internet connection that allows remote data entry and, for part B, video conferencing.
排除标准
- •1) Age <18 years. 2) HbA1c at screening visit: <7.0% or >10.0%. 3) Patient not willing to self-manage insulin titration algorithm. 4) Type 1 diabetes mellitus. 5) Treatment with mixed insulin (premixes) during the 3 months before the screening visit. 6) Use of systemic glucocorticoids (excluding topical application or inhaled forms) for two weeks or more within 8 weeks prior to the time of screening. 7) Any clinically significant abnormality identified at the time of screening, or any condition (including known substance or alcohol abuse, or psychiatric disorder) that in the opinion of the Investigator or any sub-Investigator would make implementation of the protocol or interpretation of the study results difficult or would preclude the safe participation of the participant in this study. 8) Use of any investigational drug within 1 month or 5 half-lives, whichever is longer, prior to screening visit. 9) Participant is the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol. 10) Participant whom the investigator deems otherwise ineligible (e.g. unable to understand and follow instructions). Reason for ineligibility will be documented. 11) Pregnant or breastfeeding woman at the time of screening. 12) Woman of childbearing potential not protected by acceptable method(s) of birth control and/or who are unwilling or unable to be tested for pregnancy (see Section 10.3). 13) Known hypersensitivity / intolerance to insulin glargine or any of Toujeo® excipients. 14) Participant who withdraws consent during the screening (participant who is not willing to continue or fails to return). 15) Despite screening of the participant, enrolment is stopped at the study level.
研究者
相似试验
已完成
不适用
European Comparative Effectiveness Research on Internet-based Depression TreatmentF32F33Depressive episodeRecurrent depressive disorderDRKS00006866ehrstuhl für Klinische Psychologie und Psychotherapie Friedrich-Alexander Universität Erlangen-Nürnberg1,012
招募中
3 期
Comparison of seizure generating versus non-seizure generating electroconvulsive therapy (ECT) for treating depressioCTRI/2024/03/064734All India Institute of Medical Sciences New Delhi
尚未招募
3 期
A clinical trial to compare the effect of two drugs, dexmedetomidine and esmolol as blood pressure controlling agents in patients undergoing ENT surgeries.CTRI/2017/03/008077Dr Shilpa bansal60
撤回
不适用
A European, Multi-Centre Study to Evaluate the Value of Real-Time Elastography in the Diagnosis of Prostate CarcinomaProstate adenocarcinoma10038364prostate cancerNL-OMON38888Academisch Medisch Centrum30
已完成
不适用
to study the effectiveness of ECT and tDCS in depression patients not responding to drugsCTRI/2018/06/014545Ahana Hospitals LLP90